Healthcare solutions company Evolent Health (NYSE: EVH) met Wall Street’s revenue expectations in Q3 2026, with sales up 51.3% year on year to $725.4 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.06 per share was in line with analysts’ consensus estimates.

Is now the time to buy EVH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Evolent Health’s latest quarter reflected steady progress on its core business initiatives, with management emphasizing the expansion of its Performance Suite and renewed customer partnerships as key drivers. CEO Seth Blackley highlighted the successful renewal of its largest Surgical Management contract and early signs of margin improvement, noting, “Our customers are not just staying with us, they’re asking us to do more for them.” The company also pointed to product innovation—particularly its AI-driven AuthIntelligence platform and expanded oncology care solutions—as central to advancing operational efficiency. Despite sequential growth, management acknowledged that certain one-off credits in the prior quarter created a challenging comparison for some business lines.

Looking ahead, Evolent Health’s full-year guidance is underpinned by expectations for contract maturation, incremental membership growth, and continued investment in artificial intelligence. CFO Mario Ramos emphasized the importance of AI-driven automation initiatives, stating, “We expect these initiatives to begin generating returns in late 2027, primarily in the form of cost reductions.” Management also flagged strategic priorities such as margin improvement, disciplined growth in new contracts, and ongoing cost reviews. The company is monitoring policy developments that could affect Medicaid and exchange membership, but current guidance assumes no material regulatory changes.

Key insights from management’s remarks

Management attributed the quarter’s performance to expanding client relationships, disciplined cost management, and advances in AI-powered automation across its specialty care offerings.

• Performance Suite momentum: Client renewals and expansions, including a four-year extension with the largest Surgical Management customer, anchored growth and reflected customer trust in Evolent’s model for managing musculoskeletal and cardiovascular care.

• Oncology care expansion: The company secured a significant contract to extend its oncology offering to additional states, introducing Member Navigation for over a million new commercial lives. This broadening of scope demonstrates Evolent’s ability to cross-sell and deepen existing client relationships.

• National payer scale: Evolent expanded its Specialty Technology and Services presence with a national payer, adding coverage in 11 more states and now managing approximately 7 million lives nationwide for this client. The rollout included a new cancer care model aiming to reduce prior authorization burden for providers.

• AI platform deployment: The AuthIntelligence platform advanced from pilot to broad deployment, processing about 1 million cases per year and improving auto-authorization rates by up to 20 percentage points in targeted specialties. Management cited meaningful cost savings and potential margin expansion as a result.

• Operational discipline: The company reported sequential improvement in medical expense ratio and controlled staffing costs, attributing margin gains to favorable claims development and ongoing efficiency initiatives.

Drivers of future performance

Evolent’s outlook for the coming quarters is driven by contract maturation, AI-enabled cost reductions, and focused margin management.

• Contract maturation tailwinds: As recent partnerships and renewals progress, management expects a full year of contributions from major launches with Aetna and Highmark, supporting improved earnings and cash generation.

• AI-driven efficiency gains: Expansion of the AuthIntelligence platform is projected to automate a growing share of manual authorizations, with over 80% of manual cases targeted for automation by 2027. Management believes this will drive significant operating cost reductions and support margin expansion.

• Disciplined growth and investment: The company intends to prioritize margin and cash flow over top-line growth, selectively pursuing new contracts that align with strategic and profitability objectives. Management also highlighted higher capital expenditures for AI initiatives in 2027, with returns expected to materialize in the second half of the year.

Catalysts in upcoming quarters

In future quarters, the StockStory team will be tracking (1) the pace of AI platform adoption and its impact on cost efficiency, (2) the success of new client expansions in oncology and Member Navigation, and (3) the company’s progress on debt reduction and capital allocation. Execution on these priorities, along with stabilization in membership trends and ongoing contract maturation, will be key markers of Evolent’s ability to deliver on its margin and cash flow objectives.

Evolent Health currently trades at $4.55, down from $4.80 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.